Ramos-Bustamante L

Language: Spanish
References: 6
Page: 35-36
PDF size: 51.16 Kb.

Text Extraction

No abstract

REFERENCES

1. Bartalena L, Marcocci C, Bogazzi F et al. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med 1993; 338: 73-78.

2. Heufelder AE. Pathogenesis of ophthalmopathy in autoimmune thyroid disease. Rev Endocr Metab Disord 2003; 1: 87-95.

3. Bartalena L, Baldeschi L, Dickinson A et al. Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 2008; 158: 273-285.

4. Perros P, Crombie AL, Kendall-Taylor P. Natural history of thyroid associated ophthalmopathy. Clin Endocrinol 1995; 42: 45-50.

5. Abalovich M, Llyesuy S, Gutierrez S et al. Peripheral parameters of oxidative stress in Graves’ disease: the effects of methimazole and 131 iodine treatments. Clin Endocrinol 2003; 59: 321-327.

6. Akarsu E, Buyukhatipoglum H, Aktaran S et al. Effects of pulse methylprednisolone and oral methylprednisolone treatments on serum levels of oxidative stress markers in Graves’ phthalmopathy. Clin Endocrinol 2011; 74: 118-124.